Truist analyst Srikripa Devarakonda raised the firm’s price target on Scholar Rock (SRRK) to $55 from $44 and keeps a Buy rating on the shares. The firm says it remains a buyer of Scholar Rock shares following today’s EPS call where management remains positive on the developments at Catalent and the company’s ability to resubmit apitegromab’s Biologics License Application in 2026, potentially supporting the Food and Drug Administration approval and launch in year-end 2026, which would be upside to Truist’s base case of early 2027 launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock reports Q4 EPS (88c), consensus (88c)
- Scholar Rock Advances Apitegromab Toward SMA Commercial Launch
- Scholar Rock Holding (SRRK) Q4 Earnings Cheat Sheet
- Scholar Rock’s New FORGE Study Puts Apitegromab to the Test in FSHD
- Raising Conviction on Scholar Rock: Dual Supply Chain and Broad Apitegromab Adoption Underpin Buy Rating and Higher Target